A rare association exists between pulmonary hypertension (PH) and hematologic malignancies, particularly AML evolving from MPN. The case study involves a 32-year-old woman with JAK2 mutation-positive ...
Ateganosine combined with Libtayo shows improved progression-free survival in advanced non-small cell lung cancer, suggesting potential long-term use. Spevatamig, a bispecific antibody, is being ...
– Builds on CRi rate of 60% in MB-105 monotherapy AML trial last cohort (N=5) – MB-107: Phase 1B median extended overall survival of 11 months for heavily pre-treated subjects (N=15) – MB-107 Phase 1B ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback